Claims for Patent: 10,105,418

✉ Email this page to a colleague

Summary for Patent: 10,105,418

Title:	Oral administration of tocilizumab treatment of autoimmune disease
Abstract:	The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of tocilizumab.
Inventor(s):	Brod; Staley A. (Bellaire, TX)
Assignee:
Application Number:	14/139,122
Patent Claims:	1. A method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering tocilizumab to the subject; wherein said autoimmune condition is multiple sclerosis or rheumatoid arthritis. 2. The method of claim 1, wherein the tocilizumab is administered in a liquid form. 3. The method of claim 1, wherein the tocilizumab is administered in a solid form. 4. The method of claim 1, wherein tocilizumab is administered in a dose from 1.0 .mu.g to 50 .mu.g. 5. The method of claim 4, wherein tocilizumab is administered in a dose from 1 .mu.g to 10 .mu.g. 6. The method of claim 1, wherein said tocilizumab administration decreases levels of IL-6, Th1-like cytokines IL-2, IL-12, TNF-.alpha. and IFN-.gamma.. 7. The method of claim 1, wherein said tocilizumab administration increases levels of IL-4, IL-10 and IL-13. 8. The method of claim 1, further comprising administering a compound selected from the group consisting of a SIRS peptide, .alpha.-MSH, ACTH and SST. 9. A method for decreasing innate inflammatory cytokines IL-1.beta. and TNF-.alpha., Th1-like cytokines IL-2 and IFN-.gamma., IL-17 (T.sub.eff), IL-12p70 and increasing the Th2-like counter-regulatory cytokine IL-13 in a human subject comprising orally administering tocilizumab to the subject. 10. The method of claim 9, wherein the tocilizumab is administered in a liquid form. 11. The method of claim 9, wherein tocilizumab is administered in a solid form. 12. The method of claim 9, wherein tocilizumab is administered in a dose from 1.0 .mu.g to 50 .mu.g. 13. The method of claim 12, wherein tocilizumab is administered in a dose from 1 .mu.g to 10 .mu.g. 14. The method of claim 9, further comprising administering a compound selected from the group consisting of a SIRS peptide, .alpha.-MSH, ACTH and SST.

Details for Patent 10,105,418

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010	10,105,418	2033-12-23
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	October 21, 2013	10,105,418	2033-12-23
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	November 19, 2018	10,105,418	2033-12-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.